159 related articles for article (PubMed ID: 15123286)
1. Synthesis and target identification of hymenialdisine analogs.
Wan Y; Hur W; Cho CY; Liu Y; Adrian FJ; Lozach O; Bach S; Mayer T; Fabbro D; Meijer L; Gray NS
Chem Biol; 2004 Feb; 11(2):247-59. PubMed ID: 15123286
[TBL] [Abstract][Full Text] [Related]
2. Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine.
Sharma V; Tepe JJ
Bioorg Med Chem Lett; 2004 Aug; 14(16):4319-21. PubMed ID: 15261294
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cytokine production by hymenialdisine derivatives.
Sharma V; Lansdell TA; Jin G; Tepe JJ
J Med Chem; 2004 Jul; 47(14):3700-3. PubMed ID: 15214798
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolo[2,3-c]azepine derivatives: a new class of potent protein tyrosine phosphatase 1B inhibitors.
Xie J; Tian J; Su L; Huang M; Zhu X; Ye F; Wan Y
Bioorg Med Chem Lett; 2011 Jul; 21(14):4306-9. PubMed ID: 21696953
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A.
Defauw JM; Murphy MM; Jagdmann GE; Hu H; Lampe JW; Hollinshead SP; Mitchell TJ; Crane HM; Heerding JM; Mendoza JS; Davis JE; Darges JW; Hubbard FR; Hall SE
J Med Chem; 1996 Dec; 39(26):5215-27. PubMed ID: 8978850
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety.
Lai YS; Mendoza JS; Jagdmann GE; Menaldino DS; Biggers CK; Heerding JM; Wilson JW; Hall SE; Jiang JB; Janzen WP; Ballas LM
J Med Chem; 1997 Jan; 40(2):226-35. PubMed ID: 9003521
[TBL] [Abstract][Full Text] [Related]
7. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
[TBL] [Abstract][Full Text] [Related]
8. A new glycociamidine ring precursor: syntheses of (Z)-hymenialdisine, (Z)-2-debromohymenialdisine, and (+/-)-endo-2-debromohymenialdisine.
Papeo G; Posteri H; Borghi D; Varasi M
Org Lett; 2005 Dec; 7(25):5641-4. PubMed ID: 16321011
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationship of 4-substituted 2-(2-acetyloxyethyl)-8-(morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors.
Kravchenko DV; Kuzovkova YA; Kysil VM; Tkachenko SE; Maliarchouk S; Okun IM; Balakin KV; Ivachtchenko AV
J Med Chem; 2005 Jun; 48(11):3680-3. PubMed ID: 15916416
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine.
White AW; Carpenter N; Lottin JR; McClelland RA; Nicholson RI
Eur J Med Chem; 2012 Oct; 56():246-53. PubMed ID: 22995819
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors.
Saleem RS; Lansdell TA; Tepe JJ
Bioorg Med Chem; 2012 Feb; 20(4):1475-81. PubMed ID: 22285028
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1.
Choi HS; Wang Z; Richmond W; He X; Yang K; Jiang T; Sim T; Karanewsky D; Gu XJ; Zhou V; Liu Y; Ohmori O; Caldwell J; Gray N; He Y
Bioorg Med Chem Lett; 2006 Apr; 16(8):2173-6. PubMed ID: 16458503
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of echiguanine analogs and their ribofuranosyl glycosides that inhibit phosphatidylinositol 4-kinase.
Saito Y; Kato K; Umezawa K
Nucleic Acids Symp Ser; 1997; (37):13-4. PubMed ID: 9585975
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and CHK1 inhibitory potency of Hymenialdisine analogues.
Parmentier JG; Portevin B; Golsteyn RM; Pierré A; Hickman J; Gloanec P; De Nanteuil G
Bioorg Med Chem Lett; 2009 Feb; 19(3):841-4. PubMed ID: 19111462
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and anticancer activity evaluation of some novel pyrrolo[1,2-a]azepine derivatives.
Belal A
Arch Pharm (Weinheim); 2014 Jul; 347(7):515-22. PubMed ID: 24729464
[TBL] [Abstract][Full Text] [Related]
16. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE
ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
Wang S; Wood G; Meades C; Griffiths G; Midgley C; McNae I; McInnes C; Anderson S; Jackson W; Mezna M; Yuill R; Walkinshaw M; Fischer PM
Bioorg Med Chem Lett; 2004 Aug; 14(16):4237-40. PubMed ID: 15261277
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of novel ageladine A analogs showing more potent matrix metalloproteinase (MMP)-12 inhibitory activity than the natural product.
Ando N; Terashima S
Bioorg Med Chem Lett; 2009 Sep; 19(18):5461-3. PubMed ID: 19665375
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of a diazepanone-based library of liposidomycins analogs as MraY inhibitors.
Mravljak J; Monasson O; Al-Dabbagh B; Crouvoisier M; Bouhss A; Gravier-Pelletier C; Le Merrer Y
Eur J Med Chem; 2011 May; 46(5):1582-92. PubMed ID: 21377772
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationships of novel pyrrolocarbazole lactam analogs as potent and cell-permeable inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
Wells GJ; Bihovsky R; Hudkins RL; Ator MA; Husten J
Bioorg Med Chem Lett; 2006 Mar; 16(5):1151-5. PubMed ID: 16359865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
